View Post

Modra Pharmaceuticals Announces First Patients Treated in Phase IIa Metastatic Breast Cancer Trial

In Clinical Trials by Barbara Jacoby

From: Modra Pharmaceuticals B.V. (“Modra”) today announced that the first patients have been treated in its Phase IIa study in patients with recurrent or metastatic HER-2 negative breast cancer. The trial will evaluate the efficacy and safety of Modra’s lead product, ModraDoc006/r, a proprietary oral therapeutic based on the standard intravenous taxane chemotherapy, docetaxel. In addition to enabling patients …